5-(3-Chlorophenyl)-5-[5-(oxiran-2-yl)pentyl]imidazolidine-2,4-dione | 1318777-12-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 英文名称: 5-(3-Chlorophenyl)-5-[5-(oxiran-2-yl)pentyl]imidazolidine-2,4-dione
• CAS: 1318777-12-6
• 化学式: C₁₆H₁₉ClN₂O₃
• 分子量: 322.791
• InChiKey: WICDVCORIJIMGN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  22
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  70.7
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  3-氯苯腈 在 碳酸氢钠 、 间氯过氧苯甲酸 作用下， 以 乙醚 、 乙醇 、 二氯甲烷 、 水 为溶剂， 反应 216.0h， 生成 5-(3-Chlorophenyl)-5-[5-(oxiran-2-yl)pentyl]imidazolidine-2,4-dione
  参考文献：
  名称：

  苯妥英荧光类似物作为神经性疼痛和显像剂的潜在抑制剂的合成和生物学评价

  摘要：

  在这里，我们报告了一种新型的苯妥英荧光类似物，它是一种潜在的神经性疼痛抑制剂，具有作为显像剂的潜在用途。化合物2将庚基侧链和丹酰部分并入母体化合物苯妥英，并产生更大的 BTX 从钠通道的置换和更大的功能阻断，同时大大降低了毒性。化合物2减少了大鼠神经性疼痛模型中的机械性异常性疼痛，并使用双光子显微镜在感觉神经元轴突中离体观察。这些结果为开发具有成像能力的新型钠通道抑制剂提供了一种很有前景的策略。

  DOI：

  10.1016/j.bmc.2012.06.042

文献信息

• NA CHANNELS, DISEASE, AND RELATED ASSAYS AND COMPOSITIONS
  申请人：Brown Milton L.

  公开号：US20110230442A1

  公开（公告）日：2011-09-22

  Disclosed are molecules and their synthesis, for use in blocking gated ion channels such as voltage-gated sodium channels (VGSCs) and prostate voltage sodium channels (PVSCs). These inhibitors have superior blocking efficacy, for instance in displacing the radioligand [ 3 H]-Batrachotoxin-B ([ 3 H]-BTX-B) that binds to site 2 of a VGSC. The molecules of the invention comprise a moiety which increases the binding affinity of molecules for the protein binding site in prostate cancer cells (PCs), and which is also fluorescent. In one embodiment the invention molecules are an inhibition system that can be used to target over-abundant or hyperactive VGSCs selectively in pain, epilepsy or prostate cancer, inhibiting the proliferation of PCs. The fluorescent moiety also facilitates screening, tracking, and pharmacodynamic studies of the drug in a biological system both in vitro and in vivo.

  本发明涉及分子及其合成，用于阻断门控离子通道，例如电压门控钠通道（VGSC）和前列腺电压钠通道（PVSC）。这些抑制剂具有卓越的阻断效力，例如在取代结合到VGSC的位点2的放射性配体[3H]-Batrachotoxin-B ([3H]-BTX-B)方面。本发明的分子包括一个基团，增加分子对前列腺癌细胞（PC）中蛋白质结合位点的结合亲和力，并且也是荧光的。在一种实施方式中，本发明的分子是一种抑制系统，可用于选择性地靶向过度丰富或过度活跃的VGSC，从而抑制疼痛、癫痫或前列腺癌的PC的增殖。荧光基团还有助于在体外和体内生物系统中筛选、跟踪和药效学研究药物。
• US8816095B2
  申请人：——

  公开号：US8816095B2

  公开（公告）日：2014-08-26
• [EN] NA CHANNELS, DISEASE, AND RELATED ASSAYS AND COMPOSITIONS<br/>[FR] CANAUX SODIQUES, MALADIE, ET DOSAGES ET COMPOSITIONS APPARENTÉES
  申请人：UNIV GEORGETOWN

  公开号：WO2010019963A2

  公开（公告）日：2010-02-18

  Disclosed are molecules and their synthesis, for use in blocking gated ion channels such as voltage-gated sodium channels (VGSCs) and prostate voltage sodium channels (PVSCs). These inhibitors have superior blocking efficacy, for instance in displacing the radioligand [3H]-Batrachotoxin-B ([3H]-BTX-B) that binds to site 2 of a VGSC. The molecules of the invention comprise a moiety which increases the binding affinity of molecules for the protein binding site in prostate cancer cells (PCs), and which is also fluorescent. In one embodiment the invention molecules are an inhibition system that can be used to target overabundant or hyperactive VGSCs selectively in pain, epilepsy or prostate cancer, inhibiting the proliferation of PCs. The fluorescent moiety also facilitates screening, tracking, and pharmacodynamic studies of the drug in a biological system both in vitro and in vivo.
• Synthesis and biological evaluation of a fluorescent analog of phenytoin as a potential inhibitor of neuropathic pain and imaging agent
  作者：Thomas H. Walls、Scott C. Grindrod、Dawn Beraud、Li Zhang、Aparna R. Baheti、Sivanesan Dakshanamurthy、Manoj K. Patel、Milton L. Brown、Linda H. MacArthur

  DOI：10.1016/j.bmc.2012.06.042

  日期：2012.9

  Here we report on a novel fluorescent analog of phenytoin as a potential inhibitor of neuropathic pain with potential use as an imaging agent. Compound 2 incorporated a heptyl side chain and dansyl moiety onto the parent compound phenytoin and produced greater displacement of BTX from sodium channels and greater functional blockade with greatly reduced toxicity. Compound 2 reduced mechano-allodynia

  在这里，我们报告了一种新型的苯妥英荧光类似物，它是一种潜在的神经性疼痛抑制剂，具有作为显像剂的潜在用途。化合物2将庚基侧链和丹酰部分并入母体化合物苯妥英，并产生更大的 BTX 从钠通道的置换和更大的功能阻断，同时大大降低了毒性。化合物2减少了大鼠神经性疼痛模型中的机械性异常性疼痛，并使用双光子显微镜在感觉神经元轴突中离体观察。这些结果为开发具有成像能力的新型钠通道抑制剂提供了一种很有前景的策略。